Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C4H11O4P.C3H8N2S |
| Molecular Weight | 258.276 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCSC(N)=N.CCOP(O)(=O)OCC
InChI
InChIKey=CSYSULGPHGCBQD-UHFFFAOYSA-N
InChI=1S/C4H11O4P.C3H8N2S/c1-3-7-9(5,6)8-4-2;1-2-6-3(4)5/h3-4H2,1-2H3,(H,5,6);2H2,1H3,(H3,4,5)
| Molecular Formula | C4H11O4P |
| Molecular Weight | 154.1015 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C3H8N2S |
| Molecular Weight | 104.174 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
TrioxBio's API, S-ethylisothiouronium diethylphosphate, MTR-104 (MTR- 105), is a nitric oxide synthase (NOS) inhibitor which blocks the production of nitric oxide, preventing the dilation of blood vessels and the other detrimental effects caused by excessive NOS activity. MTR-105, a
fast-acting synthetic NOS inhibitor with rapid onset of action when administered parenterally, has
been effective in alleviating hypotension experimentally
and in several observational studies while reducing NO
production. MTR-105 is registered and approved for clinical use in the Republic of Moldova where data have been
collected from 434 patients exposed to the drug in pre- and postapproval clinical investigations.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Depletion of circulating blood NOS3 increases severity of myocardial infarction and left ventricular dysfunction. | 2014-01 |
|
| Role of ion channels in sepsis-induced atrial tachyarrhythmias in guinea pigs. | 2012-05 |
|
| Specificity and selectivity profile of EP217609: a new neutralizable dual-action anticoagulant that targets thrombin and factor Xa. | 2012-03-08 |
|
| Short-term regulation of tumor necrosis factor-alpha-induced lipolysis in 3T3-L1 adipocytes is mediated through the inducible nitric oxide synthase/nitric oxide-dependent pathway. | 2009-11 |
|
| Nitrosylation of ISG15 prevents the disulfide bond-mediated dimerization of ISG15 and contributes to effective ISGylation. | 2008-09-05 |
|
| Brain neuronal/inducible nitric oxide synthases and cyclooxygenase-1 are involved in the bombesin-induced activation of central adrenomedullary outflow in rats. | 2008-08-20 |
|
| Nitric Oxide does not mediate Atrogin-1/MAFbx upregulation by inflammatory mediators. | 2008 |
|
| [The estimation of the nitric oxide role in the aggravation of combined radiation-thermal injuries]. | 2005-08-06 |
|
| Calcium/calmodulin-dependent nitric oxide synthase activity in the CNS of Aplysia californica: biochemical characterization and link to cGMP pathways. | 2005-04 |
|
| L-arginine increases dopamine transporter activity in rat striatum via a nitric oxide synthase-dependent mechanism. | 2004-12-01 |
|
| Contribution of nitric oxide produced by inducible nitric oxide synthase to vascular responses of mesenteric arterioles in streptozotocin-diabetic rats. | 2004-01 |
Patents
Sample Use Guides
Thirty-six patients with an ejection fraction >50% undergoing open-heart surgery were randomly assigned to either 50 ug kg(-1) min(-1) MTR-105 (M50, n = 12), 10 ug kg(-1) min(-1) MTR-105 (M10, n = 12) or buffered phosphate solution (placebo control, n = 12). Intravenous MTR-105 was administered continuously starting at aortic cross-clamp removal and ending 6 h later. MTR-105 doses were associated with an immediate increase in systemic blood pressure (16%) and systemic vascular resistance and a decrease in cardiac index.
Route of Administration:
Intravenous
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 22:04:38 GMT 2025
by
admin
on
Mon Mar 31 22:04:38 GMT 2025
|
| Record UNII |
CTD25O6OBI
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
514615
Created by
admin on Mon Mar 31 22:04:38 GMT 2025 , Edited by admin on Mon Mar 31 22:04:38 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB194421
Created by
admin on Mon Mar 31 22:04:38 GMT 2025 , Edited by admin on Mon Mar 31 22:04:38 GMT 2025
|
PRIMARY | |||
|
CTD25O6OBI
Created by
admin on Mon Mar 31 22:04:38 GMT 2025 , Edited by admin on Mon Mar 31 22:04:38 GMT 2025
|
PRIMARY | |||
|
100000179842
Created by
admin on Mon Mar 31 22:04:38 GMT 2025 , Edited by admin on Mon Mar 31 22:04:38 GMT 2025
|
PRIMARY | |||
|
DTXSID60176093
Created by
admin on Mon Mar 31 22:04:38 GMT 2025 , Edited by admin on Mon Mar 31 22:04:38 GMT 2025
|
PRIMARY | |||
|
21704-46-1
Created by
admin on Mon Mar 31 22:04:38 GMT 2025 , Edited by admin on Mon Mar 31 22:04:38 GMT 2025
|
PRIMARY | |||
|
210823
Created by
admin on Mon Mar 31 22:04:38 GMT 2025 , Edited by admin on Mon Mar 31 22:04:38 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |